Effectiveness and safety of orelabrutinib with rituximab and lenalidomide in low KPS score and elderly patients with newly diagnosed primary central nervous system lymphoma-a single-center retrospective study

Neurol Sci. 2024 Jun;45(6):2931-2934. doi: 10.1007/s10072-024-07348-4. Epub 2024 Feb 7.

Authors

Xiao-Ling Guo¹, Zi-Yu Zhao¹, Xue-Fei Guo¹, Ya-Bei Zuo¹, Jin-Ao Li¹, Zi-Yuan Nie², Jin-Hai Ren³

Affiliations

¹ Department of Hematology, The Second Hospital of Hebei Medical University, No. 215, Heping West Road, Shijiazhuang, 050000, Hebei, China.
² Department of Hematology, The Second Hospital of Hebei Medical University, No. 215, Heping West Road, Shijiazhuang, 050000, Hebei, China. 8503116578@163.com.
³ Department of Hematology, The Second Hospital of Hebei Medical University, No. 215, Heping West Road, Shijiazhuang, 050000, Hebei, China. jinhai1966@sina.cn.

PMID: 38326666
DOI: 10.1007/s10072-024-07348-4

No abstract available

Publication types

Letter

MeSH terms

Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Central Nervous System Neoplasms* / drug therapy
Female
Humans
Lenalidomide* / administration & dosage
Lenalidomide* / adverse effects
Lenalidomide* / therapeutic use
Lymphoma / drug therapy
Male
Middle Aged
Piperidines
Pyrazines / administration & dosage
Pyrazines / adverse effects
Pyrazines / therapeutic use
Pyridines
Retrospective Studies
Rituximab* / administration & dosage
Rituximab* / adverse effects
Rituximab* / therapeutic use
Treatment Outcome

Substances

Rituximab
Lenalidomide
Pyrazines
orelabrutinib
Piperidines
Pyridines